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Abstract: Hyaluronic acid (HA) is a naturally-occurring glycosaminoglycan and a major 
component of the extracellular matrix. Low levels of the hyaluronic acid receptor CD44 
are found on the surface of epithelial, hematopoietic, and neuronal cells; it is overexpressed 
in many cancer cells, and in particular in tumor-initiating cells. HA has recently attracted 
considerable interest in the field of developing drug delivery systems, having been used, as 
such or encapsulated in different types of nanoassembly, as ligand to prepare nano-platforms 
for actively targeting drugs, genes, and diagnostic agents. This review describes recent 
progress made with the several chemical strategies adopted to synthesize conjugates and 
prepare novel delivery systems with improved behaviors. 
Keywords: bioconjugates; drug delivery; hyaluronic acid; anticancer agents; imaging 
agents; genes 
 
1. Introduction 
Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all 
deaths) in 2008. Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1 
million deaths in 2030 [1,2]. Lung, stomach, liver, colon and breast cancers cause the most cancer 
deaths each year.  
Despite the enormous advances in understanding the molecular and cellular basis of cancer biology, 
and the development of improved therapies to treat malignancies, critical challenges remain in treating 
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primary and metastatic disease, especially those located in the central nervous system, pancreas, and a 
number of other areas. Moreover, current anticancer drugs present some important drawbacks, including 
low specificity and high toxicity; these place serious limitations upon their efficacy. One of the most 
promising ways to create anti-cancer drugs with improved therapeutic index is based on targeted therapy; 
in recent years, significant progress has been made in developing molecularly-targeted cancer therapies. 
In general, attempts to create tumor-selective cytotoxic drugs have focused on the physiological and 
biochemical differences existing between malignant and healthy tissues. It has been observed that, due 
to poor intra-tumoral lymphatic drainage and vascular leakage, large molecules can be made to 
preferentially accumulate at the malignant site: this phenomenon is known as the “enhanced 
permeability and retention” (EPR) effect [3]. In attempts to exploit this effect, polymeric conjugates [4], 
liposomes [5], microparticles, and nanoparticles [6] have been developed for possible use as passive 
drug delivery systems. Further, based on differences in biochemistry between cancerous and normal 
tissues, the same delivery systems have also been proposed to selectively target over-expressed tumor-
specific receptors.  
Conjugation of cytotoxic drugs with macromolecules improves their pharmacokinetic profile, 
prolonging the distribution and elimination phases. Furthermore, the slow release of active drug from 
the carrier may result in sustained high intratumoral drug levels and lower plasma concentrations of 
the active drug. In order to achieve this combined effect, a macromolecule-drug conjugate should 
preferentially release the active drug within the tumor tissue. The following components are essential 
to reach this goal: a biodegradable linkage, a suitable spacer, and a potent bioactive anticancer agent. 
Among the most widely studied macromolecules are N-(2-hydroxypropyl) methacrylamide (HPMA), 
polyglutamate, human serum albumin, dextrans, heparin, chitosan, dendrimers, multi-arm polyethylene 
glycol (PEG), and hyaluronic acid [7–9]. To date, very few macromolecular drug conjugates have 
provided the dual advantages of accumulation at the tumor site and receptor-mediated uptake; 
hyaluronic acid (HA), a naturally-occurring polysaccharide, has the potential to do so.  
The molecular weight of native HA has a wide range. In water, high molecular weight HA  
self-aggregates to form a viscous solution in which each molecule forms a sponge-like matrix with a 
radius of about 100 nanometers; this makes it a suitable candidate for passive tumor accumulation. In 
addition, HA plays an important physiological role in the tumorigenesis process, and consequently HA 
receptors are overexpressed on many types of tumor cells [10]. This feature could be exploited in drug 
delivery, by using the receptor as an anchor to attach prodrugs or nanomedicine-based delivery 
systems, through a ligand, so as to increase the efficiency of anticancer drugs. 
This review discusses recent progress and examines the various approaches that have been 
attempted to develop HA-based agents for cancer therapy and imaging, concentrating on those in 
which the active agents are covalently conjugated. For clarity’s sake, approaches employing HA as a 
formulation component, that is not bound to the drug or other active component, will not be examined. 
A rapid excursus from synthesis to pre-clinical/clinical evaluation of HA conjugates is included. 
2. Hyaluronic Acid 
Hyaluronic acid is a high molecular weight (106 –107 Da) glycosaminoglycan polymer composed of 
repeating disaccharides: ?1,3 N-acetyl glucosaminyl-? 1,4 glucuronide (Figure 1). HA is ubiquitous, 
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being the main component of extracellular matrix, and is essential for proper cell growth, structural 
stability of organs, and tissue organization. From the pharmaceutical standpoint, HA is a promising 
component, because it is biodegradable, biocompatible, nontoxic, hydrophilic, and nonimmunogenic. 
HA contains several chemical groups to which other components can be conjugated. The structure of 
HA is shown in Figure 1, where its possible chemical modification sites are also indicated (arrow). The 
carboxylate on the glucuronic acid, the N-acetylglucosamine hydroxyl, and the reducing termination, 
have all been successfully utilized in conjugation reactions with drugs. The acetyl group may be 
enzymatically removed from the N-acetylglucosamine, and is thus also a potential site for drug 
conjugation [11]. For a comprehensive review on chemical modification methods, synthetic routes to 
obtain HA derivatives, and their characterization, see Schanté et al. and Collins et al. [12,13]. 
Figure 1. Hyaluronic acid and small molecule conjugates. 
 
In adult tissues, such as the vitreous humor, synovial fluid, and the dermis, hyaluronan plays an 
extracellular, structural role that depends both on its hydrodynamic properties and on its interactions 
with other extracellular matrix components. However, hyaluronan is also concentrated in regions of 
high cell division and invasion (during embryonic morphogenesis, inflammation, wound repair, and 
cancer). Hyaluronic acid is thus also involved in tumorigenesis. 
Two HA receptors are strongly implicated in the cell signaling cascades associated with cancer 
initiation and progression: these are CD44 (cluster of differentiation 44) [14] and the receptor for 
hyaluronic acid-mediated motility (RHAMM) [15]. Furthermore, HA also interacts with ICAM-1 
(intracellular adhesion molecule-1), TLR-4 (toll-like receptor-4), HARE (HA receptor for 
endocytosis), and LYVE-1 (lymphatic vessel endocytic receptor) [16]. The CD44 receptor, which 
belongs to the family of cell adhesion molecules (CAMs), is a widely-distributed transmembrane 
glycoprotein that plays a critical role in malignant cell activities, including adhesion, migration, 
invasion, and survival.  
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CD44 mediates the internalization and metabolism of HA, and is endogenously expressed at low 
levels on various cell types in normal tissues [17], but it requires activation before it can bind to HA. 
Cellular activation can induce transition of CD44 to a high-affinity state, which is capable of binding 
HA. Transition from the inactive, low-affinity state to the active, high-affinity state of CD44 can be 
induced by ligation of antigen receptors [18], sulfation, or the action of cytokines [19]. Unlike normal 
primary cells, tumor-derived cells express CD44 in a high-affinity state, which is thus capable of 
binding and internalizing HA. Further, CD44 is reported to interact with HA of minimum length 6–8 
saccharide units [20]. Interference with the CD44-HA interaction, by targeting drugs to CD44, 
targeting drugs to the HA matrix, or interfering with HA matrix-CD44 interactions, are possible 
strategies for cancer treatment.  
3. HA Drug-Conjugates 
The earliest reports of an HA-drug conjugate designed to specifically target overexpressed CD44 
were in a 1996 study on Lewis lung carcinoma cells by Akima et al., which showed uptake of a 
fluorescent HA conjugate, of HA-conjugated mitomycin C (MMC), and of epirubicin. In a metastatic 
lung carcinoma model, HA-MMC decreased the number of metastatic lung nodules, thus increasing 
the therapeutic index, while HA-epirubicin showed no activity [21]. 
Again in 1996, two research groups, one from the pharmaceutical company Fidia, and the other 
coordinated by Prestwich, developed HA-butyrate and HA-paclitaxel. HA-butyrate, a histone 
deacetylase inhibitor, after conjugation showed increased apoptosis activity, inhibited cell growth in vitro, 
and resulted in a decreased tumor burden in vivo [22]. However, no further studies appeared after 
2001. Conversely, studies on HA-paclitaxel have proven more promising, and this avenue has given 
rise to further studies. 
3.1. HA-Paclitaxel 
Paclitaxel (PTX) is a powerful drug recommended for ovarian, breast, lung, bladder, prostate, 
melanoma, esophageal, and other types of solid tumor cancers, as well as Kaposi's sarcoma [23]. 
However, PTX administration is problematic owing to its poor solubility and relevant side effects, and 
also due to the excipients typically used in its formulation; for these reasons, conjugation with HA may 
offer advantages. In an attempt to resolve these difficulties, HA (molecular weight ~200 kDa) was 
linked to PTX through 4-bromobutyric acid, generating two ester linkages between PTX and HA 
[HYTAD1-p20 (ONCOFID-P)] (Figure 1, R = 1) [24]. ONCOFID-P, with PTX loading of 20% w/w, 
was initially developed for treating superficial bladder cancer [24]. A subsequent imaging 
biodistribution analysis of a 99mTc-radiolabeled ONCOFID-P administered by i.v., i.p., intravesical, or 
oral routes was conducted [25]; i.v. injection was followed by rapid and marked liver uptake (around 
80% of the injected dose). By contrast, imaging of the bladder, abdomen and gastrointestinal tract after 
administration showed that the radiolabeled conjugate remained compartmentally confined to the 
cavities. Thus these approaches may be relevant to locoregional treatment for transitional bladder cell 
carcinomas, ovarian cancers, and gastric tumors, respectively [25]. ONCOFID-P was subsequently 
evaluated for i.p. treatment of ovarian cancer against CD44 + OVCAR-3 and SKOV-3 human ovarian 
cancer cell lines, xenografted in nude mice [26,27]. ONCOFID-P cytotoxicity was somewhat lower 
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than that of free PTX in vitro; however, i.p. treatment with ONCOFID-P was overall more effective 
than i.v. or i.p. administered PTX: it inhibited intra-abdominal tumor dissemination, abrogated ascites, 
prolonged survival, or even resulted in a cure for the test animals. 
Currently, ONCOFID-P is in phase II marker lesion study in the intravesical therapy of patients 
with non-muscle invasive cancer of the bladder (EudraCT 2009-012274-13). Phase I studies have also 
been initiated to investigate the maximum tolerated dose and safety profile of ONCOFID-P following 
i.p. infusion, in patients affected by intraperitoneal carcinosis in ovarian, breast, stomach, bladder, or 
colon cancers [28–30]. 
The approach taken by Prestwich to deliver PTX with HA, from the chemical standpoint, involved 
creating a different, longer linkage between the two compounds; a succinate ester of adipic 
dihydrazide-modified HA (HA-ADH) was synthesized, followed by the coupling of PTX-N-
hydroxysuccinimide ester (NHS) (Figure 1, R = 2). The HA used had a molecular weight of ~11 kDa [31]. 
In vitro and in vivo studies of a similar conjugate (HA 40 kDa) were carried out by Klostergaard and 
coworkers, on different cancers/cancer models; firstly, on a xenografted human ovarian carcinoma, by 
i.p. administration [32]; and secondly, on a human squamous cell carcinoma of the head and neck, by 
i.v. administration [33]. More recently, HA-ADH-PTX was administered i.p. with metronomic dosing, 
in a study that showed such regimens to have substantial antitumor activity in ovarian carcinoma, 
likely via a predominant antiangiogenic mechanism [34]. 
In an alternative strategy, described by Xin et al. PTX was conjugated onto HA (9.8 kDa) using 
carbodiimide via amino acid linkers; an amino acid (aa) was previously linked by its carboxylic group 
onto the 2' hydroxyl group of PTX. The intermediate was then conjugated by the amino group of the 
amino acid onto the carboxylic group of HA, using carbodiimide activation [35]. HA-aa-PTX prodrugs, 
loading 10%–15% w/w of PTX, self-assembled into nanoparticles with a size of 270–280 nm having 
neutral charge. In vitro data showed that cytotoxicity was higher than that of free drug. 
Very recently, a conjugate between very low molecular weight HA (5 kDa) and PTX, through a 
direct ester linkage between 2' hydroxyl group of PTX and carboxylic acid of HA, was described [36]. 
To increase conjugate stability and solubility, the method described by Park [37] was applied: this 
involves the presence of dimethoxy-PEG (dm-PEG) to allow nanoparticle formation. Using this 
approach, two different populations of particles (2–3 nm and 80 nm) were observed. The conjugate, 
with a PTX loading dose of 8%, improved the standard chemotherapeutic drug’s efficacy in a 
preclinical model of brain metastases of breast cancer (231-Br cell line). The promising results on 
brain metastasis are apparently due to the small size of the nanoparticle conjugates, and to the ability 
of small HA conjugates to diffuse and accumulate in lesions better than larger ones, composed of 
higher molecular weight HA. In addition this approach also circumvents the blood brain barrier efflux 
transporter P-gp, enhancing cytotoxic activity inside the lesions. These data appear to be in agreement 
with other approaches to delivering PTX to brain tumors, for example those employing peptides, as in 
the case of GRN1005 [38]. 
3.2. HA Oncofid-S  
The pharmaceutical company Fidia Co. has developed another promising conjugate of HA, named 
ONCOFID-S, using SN-38 (an active metabolite of irinotecan) (Figure 1, R = 1). The most promising 
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results were achieved using a similar approach as for ONCOFID-P, with HA of 200 kDa and a 
derivatization degree of 9.5%. In vitro cytotoxicity was reported to be strong against several different 
CD44 + cell lines: colon adenocarcinoma, gastric, breast, esophageal, ovarian, and human lung cancer 
cell lines [39]. Pharmacokinetic evaluations lend support to the rationale for applying ONCOFID-S in 
the loco-regional intraperitoneal treatment of peritoneal carcinomatosis [40]. It is worth noting that 
formulations of HA with different anticancer drugs (irinotecan, doxorubicin, 5-fluorouracil) through 
HyACT® technology (Alchemia), where the drug is not covalently linked to HA, also appear to be very 
promising. HA plus irinotecan is currently in phase III trials for colorectal cancer [41].  
3.3. HA Bisphosphonates 
Third generation bisphosphonates (BP), such as zoledronic acid, exert a powerful antitumoral effect 
in a variety of human cancers [42]. With the aim of obtaining an antiosteoclastic and antineoplastic 
drug in an injectable hydrogel formulation, Varghese et al. synthesized a high-molecular-weight 
(HMW) HA (1.3 MDa) with different moieties. HA was functionalized on its carboxyl groups with 
both a hydrazide group and the bisphosphonate, by means of hydrazone linkages [43] (Figure 1, R = 3). 
The resulting compound was found to react with another proportion of HA, previously oxidized with 
periodate (as in Figure 2B), generating a hydrogel in less than 30 s. Cell internalization and cytotoxic 
properties of the HA compound were evaluated on two cell lines, which differed in terms of their cell 
surface HA receptor levels. The in vitro results showed that the HMW-HA-BP conjugate acted as a 
prodrug: HA was able to target CD44 +, but receptor-mediated endocytosis (and cytotoxicity) are only 
possible after cleavage of HMW-HA with a ubiquitous enzyme, hyaluronidase (Hase). In addition, the 
cytotoxicity of the HMW HA-BP conjugate was found to be directly proportional to cell surface HA 
receptor levels. The authors suggest that the hydrazide group of the HA-BP conjugate could also be 
used to explore hydrazone linkage of other drugs, such as doxorubicin (DOX), which could be 
integrated into the hydrogel matrix. Indeed, the synthesis and characterization of HA (150 kDa) DOX 
conjugates have very recently been reported [44] in research in which both a non-releasable amide (by 
direct linkage to DOX amine group) and an acid-sensitive hydrazone bond (through HA-ADH 
derivative, Figure 1, R = 4) were prepared; the DOX loading capacity was in the 0.2%–0.3% w/w 
range. DOX insertion caused a change in HA’s hydrophilicity profile, and self-assembly occurred, 
generating nanoparticles of 581–1600 nm. Preliminary cell toxicity data were reported.  
3.4. HA-Doxorubicin 
In a study by Cai et al., DOX and cisplatin were conjugated with HA but administered 
intralymphatically. Cisplatin was linked to the carboxyl groups of HA (35 kDa) using silver nitrate as 
activating agent; the optimal drug loading dose was 0.25% w/w (Figure 1, R = 5). The authors 
demonstrated that the intralymphatic delivery model, using the HA-cisplatin conjugate, not only 
significantly increased drug concentrations in loco-regional nodal tissues compared to the standard 
cisplatin formulation, but also exhibited sustained release kinetics [45]. A recent in vivo study on  
HA-cisplatin reported a significant improvement in antitumor efficacy, with lower toxicity compared 
to standard cisplatin, in locally-advanced head and neck squamous cell carcinoma [46]. In subsequent 
work, DOX was also reacted to HA (35 kDa) through a HA-ADH derivative, the optimal DOX loading 
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degree being in the 5%–15% (w/w) range. Extended in vivo evaluations (renal and cardiac toxicity, 
pharmacokinetics, tumor model) were reported [47]. The peritumoral injection of HA-DOX led to 
efficient intralymphatic delivery that delayed tumor progression by approximately 10 weeks, and 
increased animals’ survival in comparison to i.v. free DOX treatment. Further studies demonstrated 
that subcutaneous nanocarrier delivery of doxorubicin and cisplatin possesses significant efficacy 
combined with decreased toxicity, achieving complete pathologic tumor response [48]. 
Figure 2. Synthetic scheme of hyaluronic acid-phospolipid- (A) and polyethyleneimine (B). 
 
3.5. Boron Neutron Capture Therapy 
Boron neutron capture therapy is a promising approach for tumor therapy [49], but appropriate 
targeting is required to achieve boron concentrations that are sufficient to deliver therapeutic doses of 
radiation to the tumor, with minimal normal tissue toxicity (~20 μg/g tumor). Di Meo et al. proposed a 
bioconjugate (HApCB) composed of n-propyl carborane, linked to HA via an ester linkage, for a 
degree of substitution of approximately 30%; the result was a water-soluble derivative (Figure 1,  
R = 6). The structural and physicochemical characteristics of HApCB were described and its cellular 
uptake was evaluated in vitro on a variety of human tumor cells; HApCB produced high intracellular 
accumulation of boron atoms [50]. More recently, the same group prepared and characterized two new 
HA derivatives bearing carborane rings: hyaluronan-amidoazido-carborane, and hyaluronan-
propargylamido-carborane both caused relevant amounts of boron atoms to accumulate intracellularly 
in a variety of cancer cells [51]. The principal characteristics of HA-drug conjugates have been 
summarized in Table 1. 
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Table 1. Summary of the characteristics of the principal HA-drug conjugates. 
HA 
Mw 
(kDa) 
Drug 
Conjugation 
chemistry 
Name (or 
components) 
DL 
Particle 
size (nm) 
In vivo 
admin. 
Tumor 
model/clinics 
Effects Reference 
200  Paclitaxel Ester linkage ONCOFID-P 20 -- 
IP, 
intravesical 
Phase II bladder 
cancer 
Prolonged survival 
(preclinical) 
[24–26] 
40  Paclitaxel Ester linkage 
HA-ADH+PTX-
succ 
15–20  -- IP, IV MTN Ovarian cancer Antiangiogenic [31–34] 
5 Paclitaxel Ester linkage + dmPEG 8 -- IV 
Brain metastasis. 
breast cancer 
Inhibit tumor growth [36] 
200 SN-38 Ester linkage ONCOFID-S 9.5 -- IP 
Peritoneal 
carcinomatosis 
Increase survival [39–41] 
13000 
Aminomethylene
diphosphonate 
Hydrazone 
linkage 
HA-hydrazone 
+HA-ox 
5 --  CD44+ cells 
Inhibition after 
Hyaluronidase 
[43] 
150 Doxorubicin 
Acid-sensitive 
hydrazone or 
non-releasable 
amide linkage 
HA-ADH or amide 0.2–0.3 
581–
1600 
 
Different cell 
lines 
Similar to DOX [44] 
35 Doxorubicin 
Acid-sensitive 
hydrazone 
linkage 
HA-ADH 5–15 -- SC 
Xenografted 
human breast 
cancer 
Better than IV DOX [47] 
35 Cisplatin 
Cisplatin linked 
to the carboxyl 
groups of HA 
HA-COO-Pt 0.25 -- SC 
Xenografted 
human breast 
cancer 
Better than IV cisplatin [45] 
200 Propyl-carborane Ester linkage  30 --  
Different cell 
lines 
Uptake in CD44+ cells [50,51] 
HA, hyaluronic acid; ADH, adipic dihydrazide; DL, drug loading content (% w/w); MTN, metronomic therapy.
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4. HA Decorated Particles  
Gagomers (glycosaminoglycan cluster of particles; GAGs) are composed of lipid molecules that 
self-assemble into particulate clusters, which are then covalently coated with HMW (1.2–5 MDa) HA 
(by carbodiimide activation of carboxyl groups) at a lipid:HA ratio of 10:1 (w/w). HA is the main 
component of the particle surface; its interior contains both the lipid clusters and water regions, 
providing an intrinsic ability to accommodate both hydrophilic and hydrophobic molecules. GAGs can 
be generated as either micro-particles or nano-particles, and can encapsulate DNA, proteins, or small 
molecules with high efficiency. The HA coating naturally targets GAGs to cells expressing specific 
receptors, and gives these particles stealth properties. 
The preparation of GAGs containing paclitaxel (PTX-GAGs) was first described by Rivkin et al., 
who also reported the structural and physicochemical characterization of drug-free and PTX-loaded 
particles [52]. The cytotoxicity of PTX-GAGs was evaluated in vitro on the mouse colorectal 
carcinoma cell line CT-26, expressing CD44; toxicity was the same as that of free PTX. 
Pharmacokinetics, biodistribution and therapeutic properties of PTX-GAGs were evaluated in vivo on 
colon adenocarcinoma-bearing mice, and the results showed a good safety profile, marked tumor 
accumulation, and antitumor potency 4-fold that of Taxol®. 
More recently, Bachar et al. tested drug-free GAGs in vitro, on primary head and neck cancers and 
normal cells taken from the same patient, and demonstrated that GAGs can bind selectively to the 
cancerous cells, although the CD44 expression did not differ significantly between normal and 
malignant cells. They prepared GAGs containing mitomycin C (MMC-GAGs) and tested their 
cytotoxicity in vitro on the same cell lines; the cytotoxicity of MMC-GAGs was significantly higher 
than that of free MMC on head and neck cancers, whereas the viability of normal cells was not 
affected [53]. 
4.1. Polymeric Nanoparticles 
Several papers report HA conjugation to nanoparticles. With the aim of targeting 5-flurouracil  
(5-FU) to colon tumors, Jain et al. prepared chitosan–hyaluronic acid nanoparticles (HACTNPs) 
containing the drug. 5-FU loaded nanoparticles were prepared by the ionotropic gelation method, and 
their surface was coupled, using carbodiimide chemistry [1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC)], to the carboxylic group of HA, with chitosane amine groups forming an amide 
linkage. The structural and physicochemical characterization of HACTNP was described and its 
cellular uptake and cytotoxicity were evaluated in vitro on human colorectal adenocarcinoma HT-29 
cell line, which over-expresses the CD44 receptor. The cellular uptake and cytotoxicity results suggest 
that the 5-FU loaded HACTNP formulation leads to increased uptake in comparison with  
HA-uncoupled chitosan nanoparticles (CNTPs), and that possesses enhanced cytotoxicity in HT29 
colorectal cancer cell lines, compared with either CNTP or free 5-FU [54]. More recently, the same 
group prepared HACTNPs containing oxaliplatin, so as to investigate anticancer activity and 
biodistribution in vivo after oral administration in a murine colon-tumor model. The biodistribution 
studies indicated that the HACTNPs effectively reached the tumor, and were more effective in treating 
colon tumors compared with CNTPs or free oxaliplatin [55]. 
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Nanoparticles have also been formed by covalent conjugation of HA to polylactide-co-glycolide 
(PLGA) via a PEG-2000 spacer. Both PLGA (50:50, MW 40–75 kDa) and HA (5.7 kDa) were first 
activated with EDC and NHS, then mixed with the diamine linker. The particles, whose size was in the 
186 to 107 nm range, were loaded with DOX; they demonstrated increased effectiveness compared to 
nanoparticles of PLGA alone. Biodistribution studies showed high liver uptake, but also a significant 
concentration of HA-PEG-PLGA nanoparticles in tumor mass of Ehrlich ascites bearing mice [56]. A 
similar approach was employed to load 5FU [57], obtaining nanoparticles of 165 nm in diameter that 
demonstrated significant tumor uptake (4 h after administration) and thus anticancer activity. 
Another interesting category of polymers suitable for drug delivery, poly(butyl cyanoacrylate) 
(PBCA), can be covalently derivatized with HA. In one such study, nanoparticles were obtained 
through radical emulsion polymerization of n-butyl cyanoacrylate monomers, initiated by cerium ions 
in the presence of HA. HA-PBCA nanoparticles entrapping PTX, having a diameter of 290 nm (best 
formulation HA/BCA ratios 1:2, HA 18 kDa) were found to be more potent in suppressing S-180 
tumor growth than PTX-loaded PBCA nanoparticles or PTX injection [58]. 
HA was also conjugated via an ester linkage to ceramide (CE), a component of cellular membranes 
composed of sphingosine and fatty acid [59]. The amphiphilic conjugate was formulated with Pluronic 
85 as nanoparticles to encapsulate docetaxel. In vitro studies showed that HA-CE nanoparticles 
enhanced the intracellular drug uptake in the CD44 + MCF-7 cell line. Moreover, the multidrug 
resistance-overcoming effects of these carriers were observed in cytotoxicity tests. In vivo studies after 
i.v. administration in mice of docetaxel-loaded HA-CE nanoparticles confirmed their targeting ability 
for CD44 + tumors. HA-CE conjugate was then linked to PEG via carboxyl groups of HA in order to 
increase the circulation time of the nanoparticles in the bloodstream [60]. PEGylation resulted in 
prolonged nanoparticle circulation and reduced drug clearance rate in an in vivo model. 
HA was also directly conjugated to PLGA copolymer [61]. To this end aminated HA (obtained by 
reduction and further coupling to hexamethylene diamine) was reacted with NHS-activated PLGA and 
then the amphiphilic conjugate was used to form core-shell type nanoparticles containing DOX. 
Anticancer activity assays on CD44 + HCT-116 human colon carcinoma cells showed a selective 
uptake via receptor-mediated endocytosis. A similar approach was recently used to deliver docetaxel to 
CD44 + breast cancer [62]. In this study a deep investigation of HA-PLGA copolymers allowed 
nanoparticles to efficiently in vivo deliver docetaxel to breast cancer cells. HA was also grafted onto 
preformed PEG-PLGA nanoparticles by EDC coupling. The topoisomerase I inhibitor SN-38 was 
encapsulated to target ovarian cancer [63]. Cellular uptake and cytotoxicity of HA-PEG-PLGA 
nanoparticles were higher in CD44 + SKOV-3 and OVCAR-8 cell lines as compared to CD44- cells. 
In another approach HA was chemically linked to 5β-cholanic acid and PEG to form tumor-targeted 
nanoparticles (P-HA-NPs); anticancer drugs (including DOX and camptothecin) were successfully 
encapsulated into the lipophilic inner core [64]. Since encouraging in vitro cell-specific activity results 
and in vivo tumor-targeting characteristics were obtained, further studies were performed in order to 
encapsulate several molecules, such as for simultaneous tumor-targeted photodynamic imaging and 
therapy with a hydrophobic photosensitizer chlorin e6 or a near-infrared fluorescence imaging dye plus 
irinotecan [65,66]. Moreover, to improve the in vivo stability of P-HA-NPs photo-crosslinked 
nanoparticles loaded with PTX were prepared via UV-triggered chemical crosslinking with acrylate 
groups in the polymer structure [67]. The release profile of PTX from nanoparticles was much slower 
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than that from uncrosslinked P-HA-NPs. In addition, the photo-crosslinking procedure did not 
inhibited the in vitro CD44 receptor-mediated endocytosis and enhanced the in vivo targeting ability in 
tumor-bearing mice as a consequence of higher stability of the carriers. 
An amphiphilic conjugate was obtained by reacting HA with glycyrrhetinic acid (GA), which is the 
metabolite of the natural product glycyrrhizin exhibiting several pharmacological activities, such as 
anti-inflammatory, immune-modulating and reversing the multidrug resistance to anticancer agents [68]. 
The HA-GA conjugate was formulated as PTX-loaded nanoparticles actively targeted towards liver 
tumor. HA-GA carriers showed a higher cytotoxicity on cells that overexpress both HA and GA 
receptors. In vivo assays showed an accumulation in tumor and liver of mice. 
An interesting targeted codelivery system was obtained from an amphiphilic HA-all-trans retinoid 
acid (HRA) conjugate forming nanoparticles for potentially synergistic combination chemotherapy of 
paclitaxel and retinoic acid [69]. The HRA conjugate was obtained by reacting aminated retinoid acid 
with HA carboxyl groups. PTX-loaded HRA nanoparticles showed greater in vitro and in vivo 
anticancer activity. 
4.2. Microcarriers 
Hyaluronic acid can also be conjugated to microparticles. A first attempt in this connection aimed 
to obtain a cisplatin carrier that could attach itself to tumor cells, once it had reached the tumor nodules 
on the peritoneal surface, after i.p. administration [70]. The microparticles were composed of cisplatin 
linked to the carboxylic groups of HA, which served as a biodegradable and biocompatible polymeric 
matrix, onto which to link the drug (27.3% drug content, w/w) and at the same time as a targeting 
agent for the CD44 receptor. It emerged that this particulate system had favorable pharmacokinetic 
characteristics, and was more effective than the parent drug in inhibiting the growth of ovarian  
cancer nodules. 
In another approach, HA was first oxidized to obtain aldehyde groups, and then linked via an 
acetylation coupling to poly(vinyl alcohol) (PVA), a polymer already used in biomedicine as bioinert 
support material [71]. In particular, PVA formed the shell of microbubbles that had an air-filled core, 
and were used as ultrasound contrast agents; this particulate system, conjugated to oxidized HA, was 
characterized. DOX was also loaded into PVA-shelled microbubbles, and liquid-filled PVA 
microcapsules were derived, with the goal of obtaining a new theranostic tool. Analysis of the in vitro 
behavior of these microcarriers showed that the HA-based coating played a key role in promoting the 
microparticles’ internalization into a CD44 + HT-29 cell line. Table 2 shows the principal 
characteristics of HA-nano and microparticle conjugates described above. 
4.3. Liposomes and Lipoplexes for Delivering Antitumoral Drugs, DNA and RNA  
HA has successfully been linked to liposomes following two different conjugation strategies. In the 
first method, HMW HA was linked via the glucuronic carboxylate to the amino reactive group of 
phosphatidylethanolamine (PE) on the surface of preformed liposomes. This amidation reaction was 
carried out after preactivating HA with a water-soluble condensing agent (EDC), by adding the 
activated HA to the liposome suspension [72–74]. 
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Table 2. Summary of the characteristics of the principal HA-nanoparticle and microparticle conjugates. 
HA Mw 
(kDa) 
Drug 
Conjugation 
chemistry 
Name (or 
components) 
EE 
(LD) 
Particle 
size (nm) 
In vivo 
admin.
Tumor model Effects Ref. 
500–1200 Paclitaxel 
Carbodiimide 
conjugation 
PTX-GAG 100 316 ± 23 IV 
Colon 
adenocarcinoma-
bearing mice 
Antitumor potency 4-
fold higher than 
Taxol® 
[52] 
750 Mitomycin C 
Carbodiimide 
conjugation 
MMC-GAG 68–97 350 ± 35  
Head and neck 
cancers cells 
Higher cytotoxicity 
compared with free 
MMC 
[53] 
15000 Oxaliplatin 
Carbodiimide 
conjugation 
Oxaliplatin-
HACTNP 
40 152 ± 5.2 Oral 
Murine model, 
colon tumor 
Higher antitumor 
potency compared with 
free drug 
[55] 
5.7 Doxorubicin 
HA linked to PLGA via 
a diamine PEG spacer 
DOX-HA-PEG-
PLGA NP 
90  186–107 IV 
Ehrlich ascites 
bearing mice 
High tumor uptake, 
reduction of tumor size 
[56] 
5.7 5-flurouracil 
HA linked to PLGA via 
a diamine PEG spacer 
5FU-HA-PEG-
PLGA NP 
80  165 IV 
Ehrlich ascites 
bearing mice 
High tumor uptake, 
reduction of tumor size 
[57] 
18 Paclitaxel 
Radical polymerization 
of HA and BCA 
monomers 
PTX-HA-PBCA 
NP 
90  290 IV 
Sarcoma bearing 
mice 
High tumor uptake, 
Reduction of tumor 
size 
[58] 
4.7 Docetaxel Ester linkage HA-CE-DOC 72 (11) 111 IV 
MCF-7/ADR 
tumor-bearing mice 
Reduction of tumor 
size in vivo 
[59] 
4.7 Docetaxel Ester linkage 
HA-CE-PEG-
DOC 
91 (12) 160 IV 
Squamous cell 
carcinoma mouse 
model 
Reduction of tumor 
size. 
[60] 
7.5 Doxorubicin Amide linkage HA-PLGA-DOX 68 (8) 72 ± 21  
Human colon 
carcinoma cells 
More efficient DOX 
internalization in 
CD44+ cells 
[61] 
5.6, 7.3 or 
8.9 
Docetaxel Amide linkage HA-PLGA-DOC 88 (3) 117 IV 
Human breast 
tumor-bearing mice 
Enhanced antitumor 
activity compared with 
free drug  
[62] 
Molecules 2014, 19   3205 
 
 
Table 2. Cont. 
HA Mw 
(kDa) 
Drug 
Conjugation 
chemistry 
Name (or 
components) 
EE 
(LD) 
Particle 
size (nm) 
In vivo 
admin.
Tumor model Effects Ref. 
234 Camptothecin Amide linkage CPT-P-HA-NP 86 (34) 320 ± 13 IV 
Ovarian carcinoma-
bearing mice  
Specific tumor 
accumulation  
[64] 
234 Chlorin e6 Amide linkage Ce6-HA-NP 62 (12) 227 ± 12 IV 
Human colon 
cancer-bearing mice 
Increased antitumor 
efficacy  
[65] 
234 
NIR-
fluorescence 
dye 
Amide linkage Cy5.5-P-HA-NP -- 237–424 IV 
Human colon 
cancer-bearing mice 
Specific tumor 
accumulation  
[66] 
234 Irinotecan Amide linkage IRT-P-HA-NP 62 (19) 238 ± 7 IV 
Human colon 
cancer-bearing mice 
Higher antitumor 
activity and reduction 
of systemic toxicity 
[66] 
10 Paclitaxel Amide linkage HA-GA-PTX 92 (31) 321 ± 2.5 IV 
Human breast 
carcinoma  
Specific tumor 
accumulation  
[68] 
10 Paclitaxel Amide linkage 
PTX-loaded 
HRA 
91 (29) 149 ± 10 IV 
Subcutaneous 
melanoma  
Specific tumor 
accumulation 
[69] 
600–1200 Cisplatin 
Cisplatin linked to the 
carboxyl groups of HA 
HA-Cisplatin-
Microparticles 
 50 580 IP 
Ovarian cancer 
tumor-bearing mice 
Slowing the growth of 
tumor 
[70] 
700 Doxorubicin 
Interfacial acetalization 
reaction 
HA-PVA-DOX 
Microparticles 
-- --  
Human colon 
cancer-bearing mice 
The effect of DOXO 
within the first 3 days 
is cytostatic 
[71] 
EE, encapsulation efficacy (%); LD, drug loading content (w/w%); GAG, glycosaminoglycan cluster of particles; HACTNPs, chitosan–hyaluronic acid nanoparticles; 
PLGA, polylactide-co-glycolide; PBCA, poly(butyl cyanoacrylate); CE, ceramide; HRA, HA-all-trans retinoid acid; PVA, poly(vinyl alcohol); MCF-7/ADR, breast cancer 
adriamycin resistant line. 
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This approach offers the advantage that HA is only conjugated on the particle surface; however, the 
reaction leads to multipoint attachment of the polymer on the liposomes, and consequently the density 
of attachment is difficult to control and to characterize. 
HMW-HA was used, in studies by Peer et al [73], to decorate liposomes encapsulating anticancer 
drugs. In a first study, MMC was encapsulated in HA-liposomes, and their in vitro and in vivo 
behavior was compared to that of plain liposomes. The cytotoxic activity of the drug encapsulated into 
HA-liposomes was found to be 100-fold that of free drug, in tumor cell lines overexpressing the HA 
receptors, but not in cells with low receptor expression levels. In vivo studies confirmed the higher 
antitumor activity of HA-liposomes containing MMC over free drug or unmodified liposomes. The 
same group obtained similar results with DOX encapsulated in liposomes, on different tumor models, 
confirming the important and efficient targetability of HMW-HA as vector [72]. These studies 
demonstrate the advantages of HMW-HA as targeting agent for liposomes, namely: its high binding 
affinity for the CD44 receptors, its ability to provide long-term circulation in vivo, and its ability to act 
as cryoprotectant. 
In the second method, a conjugate between HA and an aminoreactive group of a lipid was prepared 
and purified, and then added to the lipid mixture during liposome preparation. With this approach, two 
different conjugation methods have been developed, depending on the molecular weight of HA. Low 
molecular weight (LMW) HA, obtained either by enzymatic degradation or from commercial sources, 
is linked to PE by reductive amination, using sodium cyanoborohydride as reducing agent, and giving 
a conjugate in which only one PE molecule is linked to HA [75,76]. This procedure enables a controlled 
amount of HA to be introduced into the liposomes, but may require more elaborate synthesis. 
The targetability of LMW-HA decorated liposomes was first demonstrated by Eliaz and Szoka [75], 
who attached HA oligosaccharides to PE, subsequently incorporating the conjugate into the liposomes. 
HA was found to increase the liposomes’ recognition by B16F10 cells expressing high levels of CD44 
in a temperature-dependent manner; uptake of the liposomes was also dependent on the density of HA 
oligosaccharide on their surface. Conversely, the control CV-1 cells, with low CD44 levels, showed 
little HA-liposome uptake. Moreover, encapsulated doxorubicin was more efficient at killing B16F10 
cells than was free drug, indicating that these HA-liposomes may provide an efficient drug delivery 
system to CD44 expressing cells. A similar approach was used by our group, to prepare HA-liposomes 
containing a gemcitabine prodrug for active targeting against pancreatic cancer cells [77,78]. 
Conjugates between 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) and two different 
LMW-HA (4.8 kDa and 12 kDa) were prepared, characterized, and introduced into liposomes during 
their preparation. In vitro studies demonstrated that HA facilitates the recognition of liposomes by 
MiaPaCa2 cells (CD44 +) and that the uptake increases as the polymer’s molecular weight increases; 
moreover, HA-liposomes also inhibited cell growth more than plain liposomes. In vivo studies showed 
that all the liposomes possessed higher antitumoral activity than free drug, in a mouse xenograft tumor 
model of human pancreatic adenocarcinoma. In particular, the 12 kDa HA-liposomes showed the 
strongest efficiency, while plain liposomes and the 4.8 kDa HA-liposomes had a similar activity.  
Cho et al. applied the above described HA-ceramide conjugate strategy [59] for the preparation of 
nanohybrid liposomes coated with HA-CE, for the targeted delivery of DOX and of a contrast agent 
for magnetic resonance imaging (Magnevist) for in vivo cancer imaging. The in vitro results showed 
the drug’s cellular uptake from nanohybrid liposomes to be higher than that of plain liposomes 
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enhanced by HA and CD44 receptor interaction. In vivo contrast-enhancing effects revealed that the 
nanohybrid liposome can be used as a tumor targeting magnetic resonance imaging probe for cancer 
diagnosis. Pharmacokinetic studies showed prolonged circulation of nanohybrid liposomes in vivo [79]. 
HMW-HA was used by our group to prepare conjugates with the fusogenic phospholipid DOPE 
(dioleoylphosphatidylethanolamine), by means of an amidation reaction [80–82] (Figure 2A). In this 
conjugate, the DOPE amino group is randomly linked to the carboxylic residues of the polymer, and 
then introduced into the cationic lipid mixture during lipoplex preparation [80]. This kind of conjugate 
can be used to deliver plasmid DNA and siRNA to CD44 + cancer cells [80–82]. The presence of 
HMW-HA in the lipoplexes was found to enhance nucleic acid protection from degradation against 
DNase I or RNAse VI. The HA-DOPE conjugate increased the transfection efficiency on MDA-MB-
231 or A549 cell lines, with high CD44 levels, compared to its effect on cell lines expressing low 
levels of CD44 (MCF-7 or Calu-3). Moreover, the transfection was markedly inhibited by using the 
anti-CD44 Hermes-1 antibody, indicating specific uptake of the lipoplexes through the CD44 receptor. 
4.4. Polyethyleneimine 
Polyethyleneimine (PEI) is one of the most widely used cationic polymer non-viral vectors [83]. 
PEI is very efficient, highly cytotoxic, due to an excess of positive charges; conjugation with HA has 
enabled carriers to be prepared with the target-specificity and biocompatibility of HA, and with a 
partial block of the positive charges, but that are still able to act as non-viral nucleic acid carrier [84–86]. 
Both HMW and LMW-HA have been used to prepare PEI-HA conjugates. When HMW-HA is 
used, the HA carboxyl groups are preactivated and then conjugated to the amines of PEI via an amide 
bond [87,88]. In these conjugates involving HMW-HA, the range of PEI:HA mass ratios explored has 
involved a larger amount of PEI than of HA within the system. The other main approach to prepare 
PEI-HA conjugates uses LMW-HA, and the synthetic method is based on reacting the primary amines 
of PEI to one of the terminal ends of the HA chain, via a reductive amination process [89]. These 
conjugates are characterized by a higher content of HA than of PEI. 
Jiang, et al. developed a novel target-specific siRNA delivery system, using PEI conjugated to 
HMW-HA [90]. The conjugates were able to efficiently complex siRNA by means of electrostatic 
interactions with the amino groups of PEI. The study demonstrated HA-specific binding in vitro, 
reporting preferred uptake and enhanced silencing effects in B16F1 cells than in HEK 293 cells, which 
do not express HA-specific receptors. 
Yao et al. synthesized a PEI-HA copolymer for targeted gene delivery, prepared by an imine 
reaction between periodate-oxidized HA of different molecular weights (60 kDa, 500 kDa, and 1500 kDa) 
and PEI (Figure 2B). Compared to the PEI/DNA complex, the PEI-HA conjugates showed an 
improved ability to form complexes with DNA, better physicochemical properties, and lower 
cytotoxicity, and they also exhibited higher transfection efficiency in HepG2 cells. The effect of HA’s 
molecular weight was also evaluated, showing that the complex prepared using HA of molecular 
weight 500 kDa was the most efficient. Moreover, the complexes that contained HA-PEI accumulated 
to a greater extent in tumor tissues after i.v. administration, compared to PEI, showing that PEI-HA 
could facilitate DNA targeting to the tumor [91]. Needham et al. conjugated PEI with HA 
oligosaccharides of different lengths, and after evaluating their ability to transfect human mesenchymal 
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stem cells, they suggested that HA containing 10 saccharide units was sufficient to enhance 
transfection efficiency [92]. A (PEI-SS)-HA conjugate has also been developed, as a target-specific 
and non-toxic delivery system for siRNA. PEI-SS was prepared by cross-linking PEI with cystamine 
bisacrylamide, and further conjugation with LMW-HA by reductive amination. The study 
demonstrated an enhanced therapeutic effect of the siVEGF/SS-PEI-HA-nanoparticles after 
intratumoral injection, compared to siVEGF/SS-PEI-particles, indicating that tumor-specific targeting 
had been conserved [93]. The same group recently described the preparation of a reducible 
HA−siRNA conjugate for target-specific systemic delivery of siRNA to the liver. The HA−siRNA 
conjugate was prepared through a disulfide exchange reaction between HA-SPDP and siRNA-SH. The 
conjugate was then complexed with PEI to form stable nanocomplexes. The results showed that 
conjugation of siRNA to HA enhances the resistance to RNase and facilitates receptor-mediated 
endocytosis. Good in vitro gene-silencing efficiency of the HA−siRNA/PEI complex was observed;  
in vivo experiments showed, further, that the complex was specifically and efficiently delivered to the 
liver [94]. 
4.5. Polymersomes 
Polymer vesicles (polymersomes) based on poly(-benzyl L-glutamate)-block-hyaluronan produced 
by click chemistry have been recently reported [95]. In this kind of system, the hyaluronan block 
favors both colloidal stability of the vesicles, by means of electrosteric effects, and interaction with 
CD44 hyaluronan receptors. DOX-loaded polymersomes have been found to efficiently encapsulate 
and deliver the drug intracellularly, in CD44 receptor-expressing C6 glioma cells in vitro. The 
cytotoxicity of these polymersomes loaded with DOX or docetaxel was determined in vitro in cancer 
cell lines expressing different levels of CD44 receptors, such as the human glioblastoma cell line 
(U87) and the human breast cancer cell line MCF7 [96]. Blood clearance and biodistribution profile 
studies, in CD44 + expressing Ehrlich Ascites Tumor (EAT) bearing Balb/C mice, were then 
performed on drug-loaded polymersomes labeled with 99mTc. Biodistribution data demonstrated that 
polymersomes accumulated at the tumor site, due both to passive accumulation (EPR effect) and to 
active targeting (CD44 mediated endocytosis) in EAT-bearing mice. Polymersome uptake in the tumor 
was greater at all time points, compared to free drug [97,98]. 
4.6. Micelles 
The hydrophilic backbone of HA can be conjugated to hydrophobic portions, giving amphiphilic 
macromolecules that can form micelles. In recent work, HA was linked via its carboxylic groups to 
amino functions of poly(L-histidine) (PHis), forming a tumor-targeted copolymer (HA-PHis) that can 
self-organize into micelles and carry anticancer drugs, such as DOX [99]. Moreover, the resulting  
HA-PHis copolymer contained pH-responsive blocks in its structure, enabling DOX to be released  
in vitro in a pH-dependent manner, exploiting the lower pH of cancer cells. In a prior study by the 
same group, another stimuli-responsive micelle material was prepared by adding an amphiphilic 
moiety (deoxycholic acid, DOCA) to HA [100]. In particular, cystamine was coupled via an amidic 
linkage to HA and DOCA and it was exploited as a bioreducible linkage to prepare redox-sensitive 
HA-deoxycholic acid (HA-ss-DOCA) PTX-loaded micelles. The degradation of these carriers depends 
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on the glutathione concentration, which acts on the disulfide bond; drug-loading capacity for PTX was 
excellent, and anticancer activity both in vitro and in vivo was higher than that of insensitive micelles 
(HA-DOCA carriers lacking the disulfide bond). PTX has also been successfully encapsulated into 
micelles characterized by a dual targeting strategy: folic acid (FA) was conjugated to HA linked to 
hydrophobic octadecyl moieties (FA-HA-C18) to give self-assembling compounds [101]. In particular, 
grafting of the octadecyl chains exploited the reaction between the carboxyl group of HA and the 
amine of octadecylamine, while FA was linked via an ester bond to the hydroxyl groups of HA. The 
dual targeting resulted in excellent uptake into cancer cells. PTX has also been directly conjugated to 
HA via an ester linkage in a single organic phase, to form nanosized micellar aggregates that release 
the drug at acidic pH [37]. These HA-PTX micelles are more cytotoxic for HA receptor-
overexpressing cancer cells than they are for HA-receptor negative cells. 
The grafting of HA to biodegradable copolymers to form DOX-loaded micelles has been reported. 
In the first such study, HA was conjugated to hydrophobic Poly[lactic-co-(glycolic acid)] (PLGA) 
using the PEG-assisted solubilization method in anhydrous DMSO; the resulting amphiphilic 
copolymer self-assembled to form multi-cored micellar aggregates [102]. DOX was entrapped during 
micelle formation, and the carriers exhibited higher cellular uptake and greater cytotoxicity on CD44 + 
than free drug. In another study, HA was grafted onto hydrophobic polylactic acid (PLA) and 
amphiphilic PEG-PLA copolymers, to obtain a hydrophobic/hydrophilic balance suitable to form 
DOX-loaded polymeric micelles in aqueous medium [103]. PEGylated micelles, which exhibited 
greater stability and had a higher drug loading capacity, were less sensitive to the adsorption of 
proteins from the cultured medium. Moreover, as shown by cytotoxicity tests on PEGylated and non-
PEGylated micelles, the presence of PEG on the carrier’s surface did not interfere with CD44 receptor 
recognition. 
HA has also been used to prepare diagnostic nanocomposite tools, as will be discussed in some 
depth below. In particular, magnetic nanoclusters were modified with HA (HA-MNCs) in a study 
aimed at detecting CD44 + breast cancer by magnetic resonance imaging [104]. To increase HA’s 
hydrophobicity, it was conjugated to 1-pyrenylbutyric acid, giving CD44-targetable surfactants that 
were then formulated with hydrophobic magnetic nanocrystals using the nano-emulsion method. HA-
MNCs exhibited superior biocompatibility and excellent properties for the targeted diagnosis of CD44-
overexpressing breast cancer in vitro and in vivo. Table 3 summarizes the principal characteristics of 
HA-conjugates reported in sections 4.3 to 4.6.  
5. Theranostic Nanoparticles Conjugated with HA 
The match between nanotechnology and oncology has given rise to a new field of interdisciplinary 
research, and several multifunctional nanocompounds have recently been developed that combine 
therapeutic and diagnostic properties. Theranostic nanomedicines, which include quantum dots, carbon 
nanotubes and nanodots, graphene, gold nanoparticles, iron oxide nanoparticles, and silica 
nanoparticles, have been found to acquire novel characteristics after their conjugation with HA.  
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Table 3. Summary of the characteristics of the principal HA-liposome, polymersome, micelle and lipoplex conjugates. 
HA Mw 
(kDa) 
Drug 
Conjugation 
chemistry 
Name (or 
components) 
EE 
(LD) 
Particle 
size (nm) 
In vivo 
admin. 
Tumor model Effects Ref. 
Nr 
Mitomycin 
C 
Amidation reaction 
HMW-HA-lip-
MMC 
53  -- IV 
Different human 
models in mice 
High tumor uptake, 
reduction of tumor size 
[72] 
Nr Doxorubicin Amidation reaction 
HMW-HA-lip-
DOX 
78  81 ± 13 IV 
Different human 
models in mice 
High tumor uptake, 
reduction of tumor size 
[73] 
0.8–3 Doxorubicin Reductive amination 
LMW-HA-lip-
DOX 
90  110–140  
Murine melanoma 
cell line 
Higher cytotoxicity 
compared with free DOX 
[75,76] 
4.8–12 
Gemcitabine 
prodrug 
Reductive amination 
LMW-HA-lip-
Gem prodrug 
89 154–192 SC 
Pancreatic 
adenocarcinoma 
cell line 
Higher cytotoxicity 
compared with free 
gemcitabine 
[77,78] 
4.7 Doxorubicin Ester linkage 
HACE-DOX-
Magnevist 
59 (1.6) 125 ± 5 IV 
Human breast 
tumor--bearing 
mice 
High tumor uptake and 
DOX prolonged 
circulation 
[79] 
1500 pDNA Amidation reaction 
HMW-HA-
DOPE-pDNA 
 250–350  
Human breast 
tumor cell line 
Transfection of pDNA 
into MDA-MB-231 cells 
[80,81] 
1500 siRNA Amidation reaction 
HMW-HA-
DOPE-siRNA 
 200  Lung cancer  
Transfection of siRNA 
into A549 cells 
[82] 
130 siRNA Amide linkage HA-PEI-siRNA  21  Murine melanoma 
Transfection of siRNA 
into B16F1 cells 
[90] 
60–500–
1500 
DNA Amide linkage HA-PEI-DNA  200 IV 
Hepatocellular 
carcinoma 
Transfection of DNA into 
HepG2 cells; 
high tumor uptake in vivo 
[91] 
6.7 siRNA Reducible SS bond 
HA-PEI-SS-
siRNA 
 110 intratumoral 
Murine colorectal 
tumor 
Inhibited tumor growth 
with reduced VEGF 
mRNA and VEGF levels 
in the tumors 
[92,93] 
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Table 3. Cont. 
HA Mw 
(kDa) 
Drug 
Conjugation 
chemistry 
Name (or 
components) 
EE 
(LD) 
Particle 
size (nm) 
In vivo 
admin. 
Tumor model Effects Ref. 
5.14 Doxorubicin 
Huisgen 1,3-dipolar 
cycloaddition 
(“Click” chemistry 
coupling) 
HA-poly(g-benzyl 
L-glutamate)-
DOX 
50 (12) 220 IV 
Rat breast 
carcinoma model 
Higher tumor uptake, 
higher tumor suppression 
and  
[96] 
5.14 Docetaxel 
Huisgen 1,3-dipolar 
cycloaddition 
(“Click” chemistry 
coupling) 
HA-poly(g-benzyl 
L-glutamate)-DOC
49 (10) 135 ± 10 IV 
Ehrlich Ascites 
Tumor  
Equipotent or more potent 
than free DOC  
[97,98] 
11 Doxorubicin 
pH responsive 
linkage 
HA-PHis-DOX 
(pH responsive) 
85–91 
(4–6) 
155–215  
Human breast 
tumor cell line 
High cytotoxicity  [99] 
11 Paclitaxel Reducible SS bond 
HA-SS-DOCA-
PTX 
93 (34) 119 ± 5  
Human breast 
tumor-bearing 
mice 
tumor accumulation  
in vivo 
[100] 
250 Paclitaxel Ester linkage FA-HA-C18-PTX 97 (9) 206 ± 14  
Human breast 
tumor cell line 
Higher cytotoxicity than 
Taxol 
[101] 
17 Doxorubicin Ester linkage HA-PLGA-DOX 31 (7) 119 ± 3  
Human colorectal 
carcinoma 
Greater cytotoxicity than 
free DOX 
[102] 
221 Doxorubicin Ester linkage HA-PLA-DOX 10 (5) 41 ± 1.5  
Human colorectal 
carcinoma and 
fibroblasts 
Less cytotoxic than free 
DOX  
[103] 
221 Doxorubicin Ester linkage 
HA-PLA-PEG-
DOX 
20 (10) 37 ± 0.8  
Human colorectal 
carcinoma and 
fibroblasts 
Less cytotoxic than free 
DOX 
[103] 
1000 
magnetic 
nanocrystals 
Amide linkage HA-MNC 78 72–138 IV 
Human breast 
tumor-bearing 
mice 
Specific tumor uptake 
(magnetic resonance 
imaging) 
[104] 
Nr, not reported; EE, encapsulation efficacy (%); LD, drug loading content (w/w%); PLA, polylactic acid; MNC, magnetic nanoclusters. 
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5.1. Quantum Dots 
Quantum dots (QDs) are nanocrystals made of semiconductor materials. They have unique light-
emitting properties that can be optimized by tuning their size and composition. QDs are made up of 
CdTe/CdSe, Cd3P2, InAs/ZnSe, and InAs/InP/ZnSe, and characteristically, they possess enhanced 
quantum photoluminiscent properties. Coating with ZnSe enhances the efficiency of QD nanoparticles. 
In order to achieve stable and improved molecular imaging, a coating around the QDs is applied using 
various ligands or organic compounds [105]; however, interaction between the coating agent and the 
QDs may lead to photoinstability [106]. Conversely, their inherent toxicity (because they release 
cadmium, although at low concentrations) restricts their possible biological applications, and several 
coating approaches are under study. 
Hahn’s group has reported some interesting results on QDs coated with HA. The conjugation 
process that they have studied involves linkage of adipic acid dihydrazide-modified HA (HA-ADH) 
onto QDs having carboxyl terminal ligands, which were activated with EDC and  
N-hydroxysulfosuccinimide (sulfo-NHS) [87,107] (Figure 3, A). QDs with an emission wavelength of 
650 and 800 nm were tested. Using HA of 130 kDa, it was found that HA-QDs conjugates with 35 
mol% ADH content, which maintain sufficient binding sites for HA receptors, mainly accumulated in 
the liver, whereas those with 68 mol% ADH content, which lose many characteristics of HA, were 
evenly distributed throughout the body tissues. Furthermore, these data were confirmed in later 
research, in which QDs with HA modified with 22 mol % ADH were submitted to real-time bio-
imaging on normal and cirrhotic mice [108]. HA-QDs conjugates were delivered in a target-specific 
manner, and accumulated more efficiently in the cirrhotic liver, where they remained even after 8 days. 
Slightly modified HA–QDs conjugates, which still had adequate binding affinity to HA receptors, 
mainly accumulated in the liver, whereas highly modified HA–QDs conjugates were evenly distributed 
throughout the body, exactly as were synthetic PEGylated QDs.  
The same approach was also employed to generate conjugates of HA with DOX; this conjugate then 
self-assembled to form micelle-like nanoparticles. To enhance their applications, the micelles were 
coated with a gold half-shell, by the thermal vapor deposition method; this may contribute to 
prolonging the residence time in the body [109].  
5.2. Carbon-Based Nanostructures 
In recent years, a family of carbon structures, including fullerene [110], carbon nanodots [111], 
carbon nanotubes (CNTs) [112], graphene [113] and graphene quantum dots [114], have attracted very 
considerable research interest, due to their superior and interesting properties, and some trial 
applications have been tested. The unique properties of nano-carbon based materials depend notably 
on their material dimensionality. For example, graphene QDs act as zero-dimensional materials, CNTs 
as one-dimensional (1D) materials, and graphene sheets as ideal two-dimensional (2D) materials. The 
inert composition of these materials is greatly beneficial, because of their biocompatible behavior, 
which is highly desirable for biological applications. In order to improve their characteristics of 
solubility and targeting, novel carbon materials have been investigated for therapeutic and bio-imaging 
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applications, after conjugation with HA. Extensive research has been carried out in this field by 
Korean scientists, and almost all carbon-based nanostructures are linked to HA.  
Figure 3. Quantum dots (A), carbon nanodots (B), graphene oxide (C), fullerene (D) 
conjugates with HA. 
 
5.2.1. Carbon Nanodots 
Carbon nanodots (Cdots) have many advantages, such as chemical inertness, lack of blinking, 
inherently low cytotoxicity, excellent biocompatibility, size- and excitation-wavelength dependent 
photoluminescence, and amphiphilic characteristics depending on the surface capping materials [115] 
Cdots have been prepared by the pyrolysis of citric acid in the presence of PEG diamine (Mw 2,000) 
as a capping material. HA Cdot conjugates were synthesized by amide bond formation between 
carboxyl groups of HA (100 kDa) and amine groups of Cdot−PEG-amine, using the carbodiimide 
reaction (EDC) (Figure 3, B). The resulting HA−Cdot conjugates had a mean particle size of 68 nm. 
The in vivo real-time bio-imaging of Cdots and HA−Cdot conjugates, in Balb/c mice, confirmed the 
target-specific delivery of HA conjugate to the liver; this is due to the abundant HARE and CD44 
receptors in that organ. Low fluorescence intensity was observed for Cdots, which might reflect the 
rapid renal clearance of Cdots having a particle size in the 5–7 nm range [116]. 
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5.2.2. Graphenes 
Very recently, graphenes and their derivatives, as single-layered carbon materials, have attracted 
considerable interest from biomedical researchers. Their unique 2-D structure provides a large surface 
area on both sides of the sheet, for the physical adsorption of nucleobases and aromatic compounds, 
mainly through π–π stacking; the functional groups, including epoxy, hydroxyl, and carboxylic acid 
moieties, that are attached to graphene oxide (GO) sheets facilitate their conjugation with 
biomolecules. Graphenes have additional advantages, including NIR photoluminescence for 
bioimaging, and photothermal effects for cancer therapy [117]. 
Li et al. [118] employed HA conjugated GO in photodynamic therapy studies. The GO was linked 
with oligo HA 5.8 kDa, by reaction with ADH and conjugation with EDC (Figure 3, C). Nanohybrids 
of 78 nm average diameter, and with about 18% of GO sheet in the HA–GO conjugate, were obtained. 
HA–GO had excellent solubility and colloidal stability, qualities that are provided by the HA 
chains. Physical loading with the photodynamic agent (chlorin e6; Ce6) was then achieved by simple 
dialysis, obtaining a loading content of Ce6 of 115%. When tested on HeLa cells, the photodynamic 
efficacy of HA–GO/Ce6 nanohybrids was ten times that of free Ce6. 
Graphene quantum dots (GQD) have attracted great interest in the biomedical field, because of their 
performance in bioimaging: they possess stable and strong fluorescence, along with electrical and 
thermal conductivity. To demonstrate the efficient delivery of GQD following receptor-mediated 
endocytosis to tumor tissue, Park and coworkers prepared HA-coated GQD. To explore their 
theranostic ability, DOX was then bound onto the surface via π–π interaction [119]. HA was anchored 
to the surface after derivatization with dopamine (degree of substitution 1.65%) by simple 
carbodiimide chemistry. The size of GQD increased, after HA anchoring, from 5–12 nm to 35–55 nm, 
but strong blue luminescence was observed in both cases. On CD44 + A549 cells the native toxicity of 
GDQ was reduced after HA-derivatization; however, compared to DOX-loaded material, there was a 
significant increase of cytotoxicity. After i.v. administration in mice, both native GQD and  
HA-modified GQD were found in the liver and kidney, as well as in tumor tissues, although double the 
quantity of HA-GQD accumulated in tumor tissues.  
5.2.3. Fullerene 
The smallest known carbon-based nanostructure, buckminsterfullerene (C60), has also received 
considerable attention in the oncological field, because it is regarded as being an excellent 
photosensitizer for use in photodynamic therapy. [120] Like the carbon nanostructures reported above, 
fullerenes are also insoluble in water and biological media and, due to their extreme hydrophobicity, 
form supra-aggregates limiting their photosensitivity. In recent work, Kwag et al. described the 
preparation of hyaluronated fullerenes [121] produced in the presence of lithium hydroxide, as 
catalyst. LiOH reacted with fullerene to break the π–π carbon bonds, after which fullerene was 
combined with the HA hydroxyl group, yielding various forms of carbon–oxygen conjugates (Figure 3D).  
By this method, using LMW-HA (4 kDa), nanoparticles of 30–60 nm were obtained; it is 
interesting that these nano conjugates exhibited NIR fluorescence, detected at 710 nm after excitation 
at 635 nm, although their fluorescence intensities gradually decreased as the degree of C60 substitution 
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increased (from 0.05 to 0.78 C60 per one sugar unit of HA). After irradiation, the compounds were 
found to be cytotoxic on CD44 + cells. After intravenous administration to nude mice bearing  
HCT-116 tumors, C60-HA effectively accumulated in the tumor tissue, although high fluorescent 
intensity was also noted in the liver. 24 h after injection of C60-HA (0.05 C60 per one sugar unit of HA) 
and laser irradiation, the tumor volume was monitored for 7 days. Notably, significant regression in 
tumor volume was observed. 
5.2.4. Carbon Nanotubes 
CNTs are graphite-like structures that are inert in nature. In terms of biomedical applications, 
carbon nanotubes have shown important potential in several areas, from tissue engineering to drug 
delivery. Regarding their applications in delivering therapeutic agents, please see a recent review [122]. 
Generally, there are three ways in which CNTs can be loaded with drugs for use in drug delivery. 
Firstly, the drug can be chemically functionalized, either permanently or via cleavable linkers, onto the 
surface of CNTs. Secondly, drugs that possess conjugated aromatic ring systems can be physically 
adsorbed onto the surface of CNTs via non-covalent π–π and hydrophobic interactions. Thirdly, some 
drugs can be encapsulated within the interior cavity of CNTs. As targeting or solubilizing agent, HA 
can be adsorbed onto the CNT surface, or may be covalently linked (either directly or after 
derivatization). 
A “complete covalent” approach has been presented by Marega et al.: HA was functionalized with 
amino groups at the primary hydroxyl groups of the N-acetyl-D-glucosamine moiety. Single-walled 
carbon nanotubes (SWCNT) are oxidized to generate carboxyl groups, using the mineral-acid-based 
wet process, after which the carboxylic groups are activated by reaction with NHS. Isolated  
ox-SWCNT-OSu is allowed to react with oligo-HA-NH2 as TBA salt, to form an oligo-HANHCO-ox-
SWCNT conjugate. The free amino groups of the oligo-HA-NH2 chains are then further functionalized 
with the anti-inflammatory drug ibuprofen, and with the anticancer drug methotrexate [123] (Figure 4A). 
No in vivo data are yet available. 
One of the most recent approaches consists of inserting cholanic-derivatized HA onto SWCNT [124]. 
Probe sonication was required to induce the hydrophobic interaction of cholanic acid with the SWCNT 
surface, and in turn disrupt the intertube van der Waals interactions. This simplified coating of  
HA-nanocarbons and purification. HA-SWCNTs were also chemically labeled with fluorescent dyes 
and a PET probe, to confirm their selective CD44 receptor uptake in cells and in vivo tests. 
Biodistribution studies on an SCC7 tumor-bearing mouse demonstrated rapid uptake and long-term 
accumulation of HA-SWCNTs in the tumor regions. 
The same approach, without the SWCNT coating, was employed in an earlier study to generate  
HA-NP, composed of only HA-cholanic and a luminescence probe [125,126]. The degree of 
substitution (number of ethyl cholanic molecules per 100 sugar residues of HA) was controlled, and 
remained in the 2–10 range. A greater degree of derivatization led to a smaller size of NP. In this 
study, which used HMW-HA (2.5 MDa), tumor targeting predominated over liver capture, especially 
for the conjugate with derivatization degree 10 (size 230 nm). Liver uptake was still significant, but 
tumor uptake was higher with HA-NP than with the HA-polymer, due to the formulation’s prolonged 
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blood survival. The study suggested that this high tumor targeting of HA-NPs might be due to a 
combination of an EPR effect, as well as to receptor-mediated endocytosis of HA-NPs. 
Figure 4. Different ways to conjugate carbon nanotubes to HA (MTX ‒ methotrexate). 
 
The covalent linkage of HA onto multiwalled carbon nanotubes (MWCNT), followed by adsorption 
of DOX, was described by Jain [127]. As a preliminary, the functionalization required the oxidation of 
MWCNT, after which the carboxyl functions were interchanged with amine groups, through a 
sequence of thionyl chloride induced acylations (24 h) and further reaction with around 3–5-fold molar 
excess of 2,2'-(ethylenedioxy) bis(ethylamine). HA of different sizes (120 and 5 kDa) was tested; 
based on the cost of HA, and the tendency of 120 kDa HA to form meshwork around the CNTs, 
LMW-HA was found to be more effective (Figure 4B). DOX was loaded into CNTs at pH 7.5–8, 
exploiting the supramolecular π–π stacking interactions between drug and nanotubes, and the increased 
lipophilicity of DOX in slightly basic solutions. A DOX loading of 33% w/w was obtained. 
Interestingly, the biodistribution profile showed that uptake to MPS organs (liver, spleen, and lung) 
was lower than it was with non-HA-derivatized or amino-decorated CNTs. Furthermore, the tumor-
CO
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specific accumulation of HA-targeted MWCNTs was around 5.79 and 3.18 times higher, respectively 
than it was with free DOX and non-HA-targeted, amino functionalized MWCNTs. Nevertheless, a 
single dose of 5 mg/Kg in rats with mammary tumor inducted with 7,12-dimethylbenz[α]anthracene 
demonstrated slightly higher antitumoral activity than that of free DOX; there was no significant 
difference between HA and HA-deprived DOX loading NTs. The same group then extended this 
approach, by comparing different drugs (DOX, PTX, methotrexate), different targeting moieties (HA, 
folic acid, estradiol) and PEG [128]. 
A similar approach was recently described by Shi et al. [129], in which HA-decorated SWCNT 
were used to deliver hematoporphyrin monomethyl ether (HMME, Hemoporfin®), a photodynamic 
therapy photosensitizer that has been in clinical trials in China since the early 1990s, to obtain a 
nanoparticle photodynamic therapy (PDT) agent. Moreover, photothermal therapy of CNTs in the NIR 
region (808 nm), and PDT of HMME in the visible light region (532 nm), were administered 
simultaneously to reinforce antitumor effects. After oxidation, the SWCNT was reacted with 
ethylenediamine and then with HA (Mw 14–20 kDa) (Figure 4C). HMME was adsorbed by sonication. 
A very high loading capacity (230% w/w) was observed. The anticancer activity of these compounds 
was tested on mouse melanoma tumor models (B16F10 cells) by intravenous administration every 2 
days, and irradiation with 532/808 nm laser. Tumors in mice in the irradiated HMME-HA CNTs arm 
showed the slowest growth after treatment (15% versus saline controls). 
5.3. Iron Oxide Nanoparticles 
The field of superparamagnetic iron oxide nanoparticles (SPION) and HA conjugated gold 
nanoparticles has not been as widely explored as that of carbon-nanostuctures. For diagnostic 
purposes, SPIONs were coated with near-infrared fluorescence dye (Cy5.5)-labeled HA [130]. 
Physicochemical analyses of Cy5.5-HA coated SPIONs demonstrated high colloidal stability and T2 
relaxivity, suggesting that they have potential as magnetic resonance probes. Furthermore, after 
treatment with hyaluronidase, the fluorescent signal of Cy5.5-HA-SPIONs increased considerably, due 
to degradation of the HA backbone.  
Based on previous research on quantum dots, which showed that HA derivatives can be delivered 
target-specifically to liver sinusoidal cells, Hahn et al. described the synthesis of HA-interferon alpha 
gold nanoparticles for targeted treatment of the hepatitis C virus [131]. A similar approach was 
followed by Huang et al. to target iron-oxide-based magnetic nanoparticles, bearing HA on the 
surface, to activated macrophages [132]. The same group exploited this synthetic procedure to cover 
both superparamagnetic iron oxide nanoparticles [133] and silica nanoparticles (see below) with HA, 
and then with DOX. Nanoparticles having a solid core of 5 nm, and a hydrodynamic diameter of 114 
nm, in which HA (31 kDa) accounted for 44% of the weight, were able to link DOX at a loading level 
of 2.1% by weight. They thereby produced a theranostic agent that combined magnetic resonance 
imaging of cancer cells with biocompatibility and cytotoxicity (Figure 5A). Furthermore, the  
DOX-HA-SPION was found to be more cytotoxic to cancer cells (including multidrug resistant lines) 
compared to free drug. 
   
Molecules 2014, 19 3218 
 
 
Figure 5. SPION (or SNP) loading HA-linked DOX (A); MSP and drug release after 
treatment with Hyaluronidase-1 (B). 
 
5.4. Silica Nanoparticles  
Mesoporous silica nanoparticles (MSP) are now attracting attention as promising components of 
multimodal nanoparticle systems, owing to their straightforward synthesis, tunable pore size, large 
loading capacity, good chemical stability, and good biocompatibility [134]. In a recent development, 
MSP-nanoreservoirs derivatized on their surface with HA have been studied, with the goal of adding 
the further advantages of enhanced biocompatibility and CD44 targeting. MSP of 100 nm and with 
pores of average diameter of 2.9 were modified with 3-(2-aminoethylamino) propyltrimethoxysilane, 
after which HA (100 kDa) was conjugated by carbodiimide reaction [135]. HA covered the pores of 
MSP, and complete release of rhodamine B, used as model drug, was achieved, but only after 
treatment with the lysosomal enzyme hyaluronidase-1 (Figure 5B). Cytotoxicity assays of MSP-HA 
loading DOX (at 68.5 µg/g SiO2) using CD44 expressing and control cell lines, showed a small, but 
significant, increase in activity on the CD44 + cells.  
Core-shell silica nanoparticles (SNP) with a fluorescent core were produced by Huang and 
coworkers, using 3-(aminopropyl)-triethoxysilane co-polymerized with tetraethylorthosilicate in an 
oil–water microemulsion. A coating of HA (31 kDa), covalently linked through amide bond, was then 
added, and increased the SNP’s solubility and CD44 targeting. In the latest step, DOX was linked to 
HA using conjugation with ADH [136] (Figure 5A). The resulting HA-DOX-SNP had a diameter of 
112 nm, loaded 31% w/w HA, and contained a DOX fraction of 0.6% w/w. The activity and specificity 
were assayed on cell lines and in 3D cell models (SKOV-3 spheroids); it was found that the HA 
coating significantly enhanced the SNPs’ tumor penetration ability and activity, including against 
DOX-resistant ovarian cancer cells, compared to free drug [137]. 
Using a similar approach, Durand et al. prepared SNP for photodynamic therapy: a core of a water-
soluble photosensitizer was entrapped in the silica framework, and then a polyelectrolyte multilayer 
was added, composed of polylysine and HA, for surface functionalization. The cytotoxicity results 
demonstrated higher phototoxic efficiency of HA-SNP after three days of growth after irradiation [138]. 
The principal characteristics of HA- nanostructures conjugates have been summarized in Table 4.
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Table 4. Summary of the characteristics of HA-nanostructures conjugates.  
HA Mw 
(kDa) Nanostructures 
Conjugation 
chemistry 
Name (or 
components) DL 
Particle 
size (nm) 
In vivo 
admin. Tumor model Effects Ref. 
130 Quantum dot (imaging) Amide linkage HA-ADH 
22, 35 68 
ADH 7–12 SC, IV Biodistribution 
22,35% liver, 68% 
tissues [106,107] 
100 Carbon nanodots (amino) Amide linkage Amide  68 IV 
Low cell toxicity, 
solubility  Liver targeting [116] 
5.8  Graphene oxide sheets, chlorin e6 Amide linkage HA-ADH  115  78  
HeLa cells, 
photodynamic Increased activity [118] 
230 Graphene quantum dots, doxorubicin Amide linkage HA-dopamine 75 35–55 IV 
CD44+ cells, 
biodistribution 
High tumor conc, 
in vitro activity  [119] 
4  Fullerene (C60) Carbon–oxygen linkage  
0.05 to 0.6 
C60/sugar 30–60 IV Cell phototoxicity 
High tumor conc, 
Inhibit tumor 
growth 
[120] 
234 SWCNTs Amide linkage HA-cholanic + cyanine, DOTA   IV Biodistribution 
High fast tumor 
uptake [124] 
234 Spontaneous nanoparticle Amide linkage 
HA-cholanic, 
cyanine  237–424 IV Biodistribution 
Prolonged 
circulation, high 
tumor uptake 
[125,126] 
120 and 
5 MWCN, doxorubicin Amide linkage 
Amide + 99mTc, 
AlexaFluor 33  IV 
In vitro, in vivo, 
biodistribution, 
toxicity 
High liver and 
tumor uptake [127] 
14–20 MWCN, Hemoporfin Amide linkage  230  IV 
Photodynamic 
therapy 
Inhibit tumor 
growth [129] 
31  SPION, doxorubicin Amide linkage Amide/HA-ADH-DOX 2.1 114  
Human monocytic 
cell line NMR+delivery [133] 
100  MSP DOX Amide linkage Amide, DOX 3,7 100 IV Human breast cancer High tumor uptake [135] 
31 Core-shell silica nanoparticles, DOX Amide linkage 
Amide/HA-
ADH-DOX  0.6 112  In vitro 3D model 
Increased tumor 
penetration [137] 
SWCNT, single-walled carbon nanotubes ; MWCNT, multiwalled carbon nanotubes; SPION, superparamagnetic iron oxide nanoparticles; MSP, Mesoporous silica 
nanoparticles; ADH, adipic dihydrazide; HA, hyaluronic acid; DL = drug loading content, expressed as % w/w. 
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6. Conclusions 
HA has been studied in considerable depth, because of its interesting physicochemical and 
biological properties, namely biocompatibility, biodegradability, non–toxicity, and non-immunogenicity. 
A further interesting characteristic is that it can easily be chemically modified, and used as a vector for 
actively targeting drugs or various carrier systems for cancer diagnosis and therapy. Much research has 
demonstrated HA’s targetability towards cancer cells overexpressing the CD44 receptor. This review 
has concentrated on the different chemical strategies adopted to synthesize conjugates and prepare 
novel delivery systems with improved performance.  
Many different chemical approaches have been used to conjugate HA to drugs, to different 
particulate carriers (micro and nanoparticles, liposomes, lipoplexes, etc) and to inorganic matrices. Of 
the numerous resulting products, one in particular, HA-PTX, known also as ONCOFID-P, which is 
administered locoregionally against bladder cell carcinoma, ovarian cancer and gastric tumors, is 
currently in phase II trials. A phase I trial has also been begun to investigate the maximum tolerated 
dose and safety profile following i.p. infusion, in patients affected by intraperitoneal carcinosis in 
ovarian, breast, stomach, bladder and colon cancers. 
The possibility of conjugating HA to particulate systems may be expected to provide opportunities 
to target cancer cells with drugs that cannot easily be linked to HA directly. Several groups report 
interesting results in various in vitro and in vivo preclinical studies dealing with targeting drug-loaded 
nanoparticles with surface-attached HA. 
Inorganic matrices (such as quantum dots, carbon nanotubes and nanodots, graphene, gold 
nanoparticles, iron oxide nanoparticles, and silica nanoparticles) have been studied in cancer therapy, 
where they have a wide range of possible applications in imaging, drug delivery, and theranostics. 
More recently, these systems have been modified by conjugation with HA, which gives them novel 
characteristics and improves their targetability; to date this approach has only been evaluated in 
preclinical studies.  
Few HA-drug delivery systems are yet in clinical trials. Several points must be studied and 
understood in depth in order to design and improve the efficacy of systems based on CD44 targeting. It 
is clear that several parameters, such as HA’s molecular weight, the site and degree of chemical 
modifications, its size and surface characteristics, can all significantly affect the interaction of  
HA-modified system with the target, avoiding preferential uptake by the reticuloendothelial system. In 
particular, in authors opinion the chemical conjugation strategies play a crucial role in the preparation, 
stability, in vitro and in vivo activity of HA-based conjugates. Further research into these and other 
parameters offer promising prospects for interesting new developments in this field. 
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